- $797.40m
- $767.39m
- $407.32m
U.S. STOCKS ON THE MOVE-Keurig Dr Pepper, Ardelyx, Vertiv
Ardelyx rises after new CFO appointment
Ardelyx Inc reports results for the quarter ended June 30 - Earnings Summary
Biopharmaceutical firm Ardelyx's Q2 revenue rises 33%
Brief: Ardelyx Inc - Enters Into Fifth Amendment To Loan Agreement - SEC Filing
Brief: Ardelyx Appoints Mike Kelliher Chief Business Officer
Ardelyx Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Ardelyx Announces Three Abstracts Accepted For Poster Presentations At Digestive Disease Week 2025 Conference
U.S. STOCKS ON THE MOVE-AerCap Holdings, Salesforce, Emcor Group
U.S. STOCKS ON THE MOVE-Cheesecake Factory, SiriusPoint, Arcutis Biosciences
U.S. STOCKS ON THE MOVE-Instacart, Spotify, First Solar
Ardelyx rises as China approves kidney disease drug
Ardelyx Inc reports results for the quarter ended December 31 - Earnings Summary
U.S. RESEARCH ROUNDUP-Biogen, Crown Castle, Eastgroup Properties
Ardelyx falls after court dismisses lawsuit against CMS over company's kidney disease drug
Brief: Ardelyx Responds To District Court Decision Granting Motion To Dismiss
Ardelyx falls after court dismisses lawsuit against CMS over company's kidney disease drug
Ardelyx Inc reports results for the quarter ended in September 30 - Earnings Summary
Brief: Ardelyx Enters Commercial Supply Agreement With Catalent Pharma Solutions